Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

Casey Butrus, PharmD; Michael Cameron, MD, FAAD, and Brittany Craiglow, MD, provide insights on the differences between therapies that require continuous use versus those that can be intermittently used for atopic dermatitis (AD), explore the potential of combination therapy, and discuss optimal efficacy and duration of therapy regimens to maximize patient outcomes.

EP: 1.Tackling Key Concerns in Atopic Dermatitis + Biologic Use

EP: 2.Atopic Dermatitis: Topical Therapies and Unmet Needs in the Treatment Landscape

EP: 3.Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment

EP: 4.Experts Discuss Long-Term Effects and Monitoring in AD Therapy

Now Viewing

EP: 5.Balancing Safety and Efficacy: Optimizing Topical Treatment Options for AD

EP: 6.The Patient Journey: Effectively Managing AD Itch Early On

EP: 7.Streamlining Prior Authorization for Topical AD Therapies: Expert Strategies

EP: 8.Experts Share Final Insights to Optimize Atopic Dermatitis Patient Care

When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
How do treatment options differ in terms of administration schedule (continuous versus non-continuous), and how does the need for breakthrough topical steroids influence your decision on therapy options?
In the managed care space, what is the role of combination therapy in AD and what restrictions might be considered?
From a payer’s perspective, how do you take into account when a product does not need continuous use and still be efficacious, potentially allowing for time off therapy?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!